A PSEN1 genetic test sequences the coding regions of the PSEN1 gene — the single gene most often responsible for early-onset Alzheimer's disease — and checks for a disease-causing variant. In a dementia second opinion, it either confirms a genetic cause behind an early or unusual presentation, or it leaves the question open, because the test finds a variant in roughly 60-80% of familial early-onset cases and misses the rest, per ARUP Laboratories' test documentation. PSEN1 stands for presenilin 1, a gene involved in processing the protein that forms amyloid plaques in Alzheimer's disease. A second opinion that includes this test is usually chasing one specific question: does a genetic variant explain why dementia symptoms showed up decades earlier than typical, or why they run through multiple generations of a family.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the PSEN1 Test Actually Measures
- Who Guidelines Say Should Actually Get Tested
- Why a Negative Result Doesn't Close the Question
- A Positive Result Doesn't Predict the Clinical Course
- How Results Are Handled in Practice
- Frequently Asked Questions
What the PSEN1 Test Actually Measures
Clinical PSEN1 testing reads through the gene's exons — the protein-coding segments — and the boundaries where they meet the surrounding non-coding sequence. Labs typically run it as part of a panel alongside APP and PSEN2, the two other genes tied to early-onset familial Alzheimer's, according to ARUP Laboratories. Among the three, PSEN1 is both the most frequently mutated and the one tied to the earliest onset, with symptoms typically appearing between ages 30 and 50, compared with the generally older onset seen in APP carriers and the rarer, later-onset PSEN2, per a 2025 slide deck from the University of Washington Memory and Brain Wellness Center.
That age range is why clinicians reach for this test specifically when a patient's dementia symptoms began well before the more common late-60s or later onset. A positive result identifies a specific variant in the gene and gives a second-opinion team a molecular explanation for the clinical picture. It also opens the door to testing at-risk relatives, since PSEN1 variants are inherited in an autosomal-dominant pattern — each child of a carrier has roughly a 50% chance of inheriting the same variant.
Who Guidelines Say Should Actually Get Tested
PSEN1 testing is not a general dementia screening tool, and guideline criteria keep it narrow on purpose. Testing is indicated for symptomatic people with early-onset dementia who have a family history of the disease (or an unknown family history), for members of families with an autosomal-dominant pattern of early-onset cases, and for relatives of someone already confirmed to carry a mutation, per a GeneReviews-based guideline summary. That means a person with typical late-onset memory loss and no strong family pattern is not the intended candidate, regardless of how urgently they want an answer.
The test is built for a specific clinical profile: unusually young onset, a family tree with multiple affected members, or a known variant already identified in a relative. Guidelines also flag a situation second-opinion teams encounter directly: a symptomatic patient tested mainly because a relative is pushing for it. In that case, the guidance is to watch for conflicts of interest and to recommend against testing — offering DNA banking instead — if the patient seems reluctant or ambivalent, per the same guideline summary. Banking preserves a DNA sample for later testing without forcing a decision the patient isn't ready to make.
Why a Negative Result Doesn't Close the Question
A negative PSEN1 panel is not the same as ruling out an inherited cause. Standard sequencing does not catch large deletions or duplications, variants buried deep in non-coding intronic regions, or low-level mosaic variants present in only a fraction of a person's cells — any of which can still cause disease even though the panel reads clean, according to ARUP Laboratories.
This is the single most important limit for someone treating a negative result as closure. A second opinion built on "the genetic test was negative, so it isn't genetic" skips over a real category of causes the test is not designed to detect. When a family history strongly suggests autosomal-dominant inheritance despite a negative panel, that's a reason to ask the second-opinion team whether a different testing method — one that can detect structural variants or deep intronic changes — is warranted, not a reason to stop looking.
A Positive Result Doesn't Predict the Clinical Course
Confirming a PSEN1 variant answers the question of cause, but it does not answer the question of what happens next. A 2013 review found no consistent relationship between which specific variant a person carries and how their disease unfolds — the exception being one variant associated with spastic paraparesis — with onset age, symptoms, and progression varying even among carriers in the same family, per a review in the Journal of Alzheimer's Disease. That unpredictability is also why PSEN1 carriers can present atypically.
A 2005 review found some carriers show features well outside the classic amnestic pattern most people associate with Alzheimer's, pointing to genetic or epigenetic modifiers that shape how the disease looks in any one person, according to a review in the Journal of Neurology. For a second opinion, this matters directly: a diagnosis that doesn't match the "textbook" PSEN1 picture isn't automatically wrong, since the gene itself produces a wide range of presentations. Because of this variability, genetic counseling before and after testing is described as essential for both symptomatic patients and healthy at-risk relatives — carriers are left facing real uncertainty about their own eventual course, not a fixed script, per a review in the American Journal of Medical Genetics Part B.
How Results Are Handled in Practice
Some research programs build the uncertainty directly into how they disclose results. The NIH National Institute on Aging's Alzheimer's Family-Based Study returns PSEN1, APP, and PSEN2 results to early-onset participants — those with onset at 65 or younger — but limits disclosure to one person per family, the earliest-onset case, and requires a structured counseling protocol both before and after the result is shared, per the study's published protocol. That structure reflects the same concerns guidelines raise for clinical testing generally: For a reader weighing a second opinion that includes PSEN1 testing, the practical takeaway is that the test is one data point inside a counseling process, not a standalone verdict — and a second-opinion team that orders it without pre- and post-test counseling is skipping a step every major guideline treats as essential.
- A result affects the whole family's risk picture, not just the person tested, so disclosure is paced deliberately rather than handed over all at once.
- Counseling before testing screens for ambivalence or family pressure; counseling after testing addresses what a positive or negative result does and doesn't mean.
- Limiting disclosure to one family member at a time keeps the counseling protocol manageable and consistent, rather than triggering simultaneous, unsupported disclosures across relatives.
Frequently Asked Questions
Does PSEN1 testing apply to typical late-onset Alzheimer's disease?
No. Guideline criteria restrict it to early-onset cases with a family history, autosomal-dominant family patterns, or relatives of a known carrier — not general-population or late-onset screening, per guideline criteria summarized on guidelinecentral.com.
If one relative tests positive for a PSEN1 variant, does that predict how severe their dementia will be?
No. A 2013 review found no consistent link between the specific variant and disease severity or progression, with substantial variation even within the same family, per the Journal of Alzheimer's Disease.
Why would a second-opinion team recommend DNA banking instead of immediate testing?
Guidelines recommend banking over testing when a patient appears reluctant or ambivalent, particularly when testing is being pursued mainly at a relative's request, per guideline criteria on guidelinecentral.com.
